Ontario Public Drug Programs

Executive Officer Communications

Date	Title
2017
July 11	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program English \| French
July 7	Notice from the Executive Officer: Ontario Drug Benefit Act, Legislative amendments to recognize the role of Nurse Practitioners in requesting Exceptional Access Program products and prescribing Listed Substances (Bill 87) English \| French – Frequently Asked Questions for Health Care Providers English \| French
June 29	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management English \| French
March 16	Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs English \| French
February 21	Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program English \| French – Frequently Asked Questions for Health Care Providers English \| French – Frequently Asked Questions for Patients English \| French
January 27	Notice from the Executive Officer: Updated Reminder Regarding Delisting of High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program English \| French
2016
December 21	Notice from the Executive Officer: Funding of Grastofil (filgrastim) under the Ontario Drug Benefit program English \| French – Frequently Asked Questions English \| French
December 1	Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program English \| French – Frequently Asked Questions English \| French
November 30	Notice from the Executive Officer: Update Regarding Palliative Care Access to High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program English \| French
October 24	Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines for 2016-2017 Season and Claims Submission using the Health Network System English \| French – Frequently Asked Questions English \| French
October 07	Notice from the Executive Officer: Application of Generic Substitution to the Exceptional Access Program English \| French – Frequently Asked Questions for Patients English \| French – Frequently Asked Questions for Pharmacists English \| French – Frequently Asked Questions for Physicians English \| French
September 26	Notice from the Executive Officer: Regulation amendments to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products English \| French
September 16	Notice from the Executive Officer: Regulation to support the Safeguarding our Communities Act, 2015 (Patch for Patch Return Program) English \| French – Frequently Asked Questions for Prescribers and Pharmacists English \| French – Frequently Asked Questions for Patients English \| French
September 16	Notice from the Executive Officer: Drug Submission – Ontario Guidelines for Drug Submission and Evaluation 2016 English \| French
September 02	Notice from the Executive Officer: Changes in the Way Social Assistance Clients Access Drug Coverage English \| French – Updated Drug Eligibility Card Pharmacy Information Sheet English \| French – Updated User Guide English \| French – Updated ODB Cannot be confirmed via HNS English \| French – Updated ODB Cannot be confirmed via HNS– Accessible version English \| French – Drug Eligibility Pharmacy Quick Reference Guide English \| French – Drug Eligibility Pharmacy Questions and Answers English \| French For Social Assistance Clients – Drug Eligibility Card Client Information Sheet English \| French – Social Assistance Client Cheque Insert - Aug./Sept. version English \| French – Social Assistance Client Cheque Insert - Oct./Nov. version English \| French
August 17	Notice from the Executive Officer: Reminder - Ontario Naloxone Program for Pharmacies (ONPP) English \| French Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP) English \| French – Frequently Asked Questions for Pharmacists English \| French – Quarterly Reporting Form English \| French
August 15	Notice from the Executive Officer: Reimbursement and Claims Submissions using the Health Network System relating to Drugs for Medical Assistance in Dying English \| French – Frequently Asked Questions for Pharmacists English \| French
July 20	Notice from the Executive Officer: Changes to the Ontario Drug Benefit (ODB) Program Funding of Opioid Medications English \| French – Frequently Asked Questions for Pharmacists English \| French
July 4	Notice from the Executive Officer: MedsCheck Program Enhancements English \| French
June 10	Notice from the Executive Officer: Health Network System (HNS) Changes to Support the Maximizing Quantity Dispensed for Chronic-Use Medications Initiative English \| French – Frequently Asked Questions English \| French
June 1	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products English \| French
June 1	Notice from the Executive Officer: Proposed Regulation under the Safeguarding our Communities Act (Patch for Patch Return Policy) English \| French
April 15	Notice from the Executive Officer: Regulation Amendments to Expand Access to the Seniors’ Co-Payment Program under the Ontario Drug Benefit (ODB) Program English \| French
March 22	Executive Officer Notice Drug Submission – Information Bulletin English \| French
March 15	Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs English \| French
March 11	Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program English \| French – Frequently Asked Questions English \| French
February 29	Notice from the Executive Officer:Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to update cost-sharing arrangements for non-low income seniors under the Ontario Drug Benefit (ODB) program English \| French
2015
November 23	Notice from the Executive Officer: New Blood Glucose Test Strip Reimbursement Policy English \| French
November 13	Notice from the Executive Officer: Claims submission for prescriptions with drug costs over $10,000 English \| French – Frequently Asked Questions English \| French
October 13	Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2015-2016 Season and Claims Submission using the Health Network System English \| French – Frequently Asked Questions updated October 2015 English \| French
September 18	Notice from the Executive Officer: Regulation Amendments to Streamline Submission Requirements for Certain Generic Products seeking Interchangeability Designations on the Ontario Drug Benefit Formulary English \| French
September 18	Notice from the Executive Officer: Regulation Amendments to Support Sustainability and Access for the Ontario Public Drug Programs English \| French
September 18	Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program English \| French – Questions & Answers for Pharmacists English \| French – Questions & Answers for Physicians English \| French – Questions & Answers for Patients English \| French – Chronic-use Medications List by Generic Name English
July 23	Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act English \| French – Questions & Answers for Patients English \| French
May 20	Notice from the Executive Officer: Tiered Generic Pricing Framework English \| French
March 10	Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs English \| French
2014
November 5, 2014	Notice from the Executive Officer: Proposed Regulation Amendments to Establish a Pricing Framework for Certain Generic Products on the Ontario Drug Benefit (ODB) Formulary English \| French
October 10	Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2014-2015 Season and Claims Submission using the Health Network System English \| French – Frequently Asked Questions updated November 21, 2014 English \| French
July 17	Notice from the Executive Officer: Methadone Maintenance Treatment - Extended Transition Period English \| French
June 26	Notice from the Executive Officer: Methadone Maintenance Treatment. – Frequently Asked Questions for Pharmacists # 2 English \| French
June 20	Notice from the Executive Officer: Methadone Maintenance Treatment Reimbursement Policy, 2014, effective June 26, 2014 English \| French Changes to Methadone Maintenance Treatment : Frequently Asked Questions for Patients English \| French Changes to Methadone Maintenance Treatment : Frequently Asked Questions for Pharmacists English \| French Changes to Methadone Maintenance Treatment : Frequently Asked Questions for Physicians English \| French
March 11	Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2014 [PDF]
March 10	Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs [PDF]
2013
November 28	Notice from the Executive Officer: Edition 42 of the Ontario Drug Benefit Formulary [PDF]
November 26	Notice from the Executive Officer: Accuracy in Claims Submissions [PDF]
October 4	Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2013-2014 Season and Claims Submission using the Health Network System english \| french
September 17	Blood Glucose Test Strip Reimbursement Update [PDF]
July 11	Notice to Pharmacies - Contacting the ODB Help Desk [PDF]
July 8	Notice from the Executive Officer: Blood Glucose Test Strip Reimbursement Policy [PDF] english \| french
June 11	Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel]
March 7	Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2013
March 4	Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs
February 20	Important Notice from the Executive Officer: Proper Submission of Prescriber Identification to the Health Network System (HNS) and Narcotics Monitoring System (NMS) [PDF]
February 13	Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel]
February 4	Notice from the Executive Officer: FINAL Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet – OxyNEO [PDF]
January 24	Notice from the Executive Officer: New Regulatory Requirements for Long-Acting Oxycodone Drug Products [PDF]
January 15	Notice from the Executive Officer: Assignment of ON Numbers to Health Network System/Ontario Drug Benefit Accounts
2012
December 20	Notice from the Executive Officer: Expanded Scope of Practice and Accuracy in Claims Submission [PDF]
December 12	Delisting of Aliskiren (Rasilez®) from the ODB Formulary - Questions & Answers
November 28	Important notice regarding the prescribing and dispensing of Oxycodone CR. english \| french
November 23	Proposed Regulation Amendments to Set Additional Conditions for Submission Requirements of Long-Acting Oxycodone Drug Products english \| french
October 10	Notice to Pharmacies – Contacting the Help Desk [PDF]
October 9	Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System; 2012-2013 Influenza Season - Fact Sheet - Q & As
October 4	Notice from the Executive Officer: Important Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet - OxyNEO [PDF]
September 27	Notice from the Executive Officer: Changes to the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program
September 24	Important Notice from the Executive Officer: Proper Submissions to the Narcotics Monitoring System (NMS) [PDF]
August 20	Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers [Excel]
August 15	Proposed Regulation Amendment to Reduce the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program
May 8	Important Notice from the Executive Officer: Submission of Monitored Drug Information to the Narcotics Monitoring System
April 12	Notice from the Executive officer. Re: Implementation of the Narcotics Monitoring System (NMS) english \| french
March 16	Notice from the Executive Officer. Re: Upcoming Changes for April 1, 2012
February 27	Notice from the Executive Officer. Re: Pharmaceutical Opinion Program
February 17	Notice from the Executive Officer: RE: Important Notice Regarding Change in Funding Status of Oxycodone Controlled Release Tablet – (Discontinuation of OxyContin and Introduction of OxyNEO) english \| french
February 6	Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers
2011
December 6	Notice from the Executive officer. Re: Prescriber ID Requirements for Claims Submitted on the Health Network System (HNS)
November 30	Notice from the Executive Officer. Re: Additional Clarification Regarding the Narcotics Legislation
October 27	Notice from the Executive Officer. Re: Additional Questions on the Narcotics Legislation english \| french
October 14	Important Notice to Health Care Providers on the New Requirements under the Narcotics Safety and Awareness Act, 2010
October 14	Public Notice Regarding the Ministry of Health and Long-Term Care's ("ministry") Collection, Use and Disclosure of Information under the Narcotics Safety and Awareness Act, 2010 english \| french
September 9	Suspension of Ontario Drug Benefit (ODB) Billing Accounts
August 31	Notice from the Executive Officer. Re: MedsCheck Program Standardization and system Requirements
August 31	Notice from the Executive Officer. Re: Pharmaceutical Opinion Program
August 29	Notice from the Executive Officer. Re: Pharmacy Smoking Cessation Program
August 22	Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for September 1, 2011
July 28	Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers
June 10	Notice from the Executive Officer. Re: Extension of Transition Fee Payments and Conditions for Payment of Dispensing Fees for Remote Dispensing Location under the Ontario Public Drug Programs
May 24	Clarification to the Notice from the Executive Officer. Re: Lucentis – Change in Status to Limited Use (April 1, 2011)
April 7	Notice from the Executive Officer. Re: New Regulation under the Optometry Act, 1991
April 4	Notice from the Executive Officer. Re: Request for Qualification (RFQ) for Acquirer Host Network Services
April 1	Notice from the Executive Officer. Re: EAP criteria change for rosiglitazone (Avandia)
April 1	Notice from the Executive Officer. Re: Lucentis - Change in Status to Limited Use
March 29	Notice from the Executive Officer. Re: Implementation of the first stage of expanded services
March 23	Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for April 1, 2011
March 23	Notice from the Executive Officer. Re: Increase in Dispensing Fees, Effective April 1, 2011
March 18	Notice from the Executive Officer. Re: New Regulation under the Drug and Pharmacies Regulation Act (DPRA)
February 28	Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers
February 09	Notice from the Executive Officer. Re: Narcotics Monitoring System Questions and Answers
2010
December 6	Notice from the Executive Officer. Re: Formulary Listing for Enalapril Maleate
October 19	Q & As for Change in Listing Status for Gabapentin
September 30	Notice from the Executive Officer. Re: Pharmacy ONE Mail System Registration - Reminder Notice
September 8	Notice from the Executive Officer. RE: MedsCheck Program Expanded Services Launched September 13, 2010
August 26	Notice from the Executive Officer: Change in Status to Limited Use (Humira and Enbrel) & New Limited Use Listing (Stelara) - Q & As for Change in Listing Status for Humira, Enbrel, and Stelara
August 23	Notice from the Executive Officer. RE: Expanding Professional Pharmacy Services Working Group
July 13	Notice from the Executive Officer: Reporting Framework for Professional Allowances
June 08	Notice from Ontario Public Drug Programs Re: Clarification of Digoxin Listings
January 25	Notice from the Executive Officer: Reporting Framework for Professional Allowances
2009
July 17	Policy to Acquire Medications for Treatment of Tuberculosis - Dear Pharmacist Letter. Communiqué from the Public Health Division, MOHLTC
July 15	Notice from the Executive Officer: Reporting Framework for Professional Allowances
May 6	Notice from the Executive Officer: Change of Funding Status Rosiglitazone (Avandia®) and Pioglitazone (Actos® and Generics) - Q&As for TZD Funding Status Change
May 6	Notice from the Executive Officer: Expanded Limited Use Criteria for Clopidogrel (Plavix) - Q&As for Clopidogrel Expanded LU Criteria
March 3	Notice from the Executive Officer - MedsCheck Adjustment Payment to Pharmacies Ending on April 1, 2009
February 23	Notice from the Executive Officer: Ongoing Transparency Initiative: Public Posting of Drug Submission Status - Updates
February 4	Notice from the Executive Officer: Reminder – Professional Allowance Reporting: July 1, 2008 to December 31, 2008
January 13	Notice from the Executive Officer: Academic Detailing Program - Q&As for Academic Detailing Program
2008
December 19	Notice from the Executive Officer: Health Network System (HNS) Enhancements to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program
December 17	Notice from the Executive Officer: Renewal of the Health Network System (HNS) Subscription Agreement
December 1	Notice from the Executive Officer: Enhancements to Health Network System to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program
December 1	Notice from the Executive Officer: Announcement of Changes to the Formulary respecting Enalapril Maleate
November 17	Notice from the Executive Officer: Telephone Request Service for Exceptional Access Program - Q&As for External Stakeholders
October 29	Executive Officer Notice: Completing the New Health Network System (HNS) Agreement
October 27	Executive Officer Notice: Price Increase Requests
October 20	Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement
October 3	Notice from the Executive Officer: Public Consultation to Review the definition of Professional Allowance and the Codes of Conduct
October 2	Notice from the Executive Officer: Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement
September 30	Notice From Executive Officer: Implementation Plan To Review The Definition Of Professional Allowance And The Code Of Conduct
September 19	Notice from the Executive Officer: Notice Of Cancellation Of Call For Application For Ranitidine Hydrochloride
August 26	Notice from the Executive Officer: Drug Submissions Requirement - Revised Letter of Consent
August 22	Notice from the Executive Officer Reminder - Professional Allowance Reporting
August 5	Notice from the Executive Officer: Claims for ZANTAC® under the Ontario Drug Benefit Program
July 28	Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program - Questions and Answers
July 18	Notice from the Executive Officer: Reporting Framework for Professional Allowances
July 16	Notice from the Executive Officer: Competitive Agreements Q&As
July 8	Notice from the Executive Officer: Ontario Public Drug Programs Competitive Agreement - Briefing for Stakeholders
June 4	Notice from the Executive Officer: Manufacturer Review of Transparency Bulletin
May 29	Notice from the Executive Officer: Pricing of Products Reimbursed Under the Exceptional Access Program (EAP)
May 16	Notice from Executive Officer
May 16	Notice from Executive Officer: Limited Use (LU) Process Changes
May 13	Notice from Executive Officer: Ongoing Transparency Initiative - Public Posting of Drug Submission Status.
April 17	Notice from the Executive Officer: Lucentis Questions and Answers
April 15	Recruitment for Pharmacy Council Members, letter from the Executive Officer
March 6	Notice from the Executive Officer: Reporting Framework for Professional Allowances
January 30	2008 BBS Notice from the Executive Officer: MedsCheck, Adjustment Payment to Pharmacies - a Reminder
2007
November 15	Notice from the Executive Officer, BBS Introducing the "Follow-up" MedsCheck, effective November 30, 2007
November 15	Recruitment for Pharmacy Council Members, letter from the Executive Officer
November 13	Notice from the Executive Officer: Reporting Framework for Professional Allowances
October 19	Notice from the Executive Officer: Reporting Framework for Professional Allowances
October 1	Notice to Manufacturers Submission Requirements for Generic Drug Products
October 4	(BBS Nº.7079) Notice from the Executive Officer: Lead Time Between the Formulary Update and Effective Date
September 14	(BBS Nº.7071) Notice from the Executive Officer: Reporting Framework for Professional Allowances
July	Letter to Pharmacists from the Executive Officer: MedsCheck Update
July 13	Notice to Pharmacists: MedsCheck Update
May 29	(BBS Nº.7029) MedsCheck Update
May 8	(BBS Nº.7025) Notice to Pharmacists from Executive Officer: Follow up to April 5, 2007 Notice
April 1	Letter to Pharmacists from the Executive Officer: MedsCheck
February 21	(BBS Nº.7009) Notice from the Executive Officer: Reporting Framework for Professional Allowances
2006
December 18	(BBS Nº.6086) Notice from the Executive Officer: Amending Regulations under ODBA and DIDFA
September 28	Notice to Pharmacists: Regulation Changes made to the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA)
April 13	(BBS Nº.6029) Notice to Pharmacists: Bill 102, Transparent Drug System for Patients Act

Ministry Status: Activation Status

Ontario Public Drug Programs

Executive Officer Communications

For More Information